BioSpace News Archive

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the successful closing of its license agreement with Eli Lilly and Company (Lilly), following the expiration of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976.

Aerie Pharmaceuticals to Participate in the 20 th Annual Needham Virtual Healthcare Conference

Medcura, Inc . , a commercial-stage medical device company, announced today that it has published the results of a peer-reviewed clinical study at the University of Chicago in this month’s Cardiovascular Catheterization and Intervention

Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, has secured $55 million from a syndicate of leading life science investors in an oversubscribed financing round.

ERC-USA and the University of California, Irvine (UCI), today announce that the FDA has recommended early termination of the onging Phase 2 clinical trial titled ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma in a letter dated April 2, 2021 (https://clinicaltrials.gov/ct2/show/NCT01903330?term=Bota&draw=2&rank=3)

Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient has been dosed in the AFFINITY Study, a phase 2 clinical trial evaluating the efficacy and safety of atrasentan, a potent and selective inhibitor of the endothelin A receptor

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (“Regulus”), today announced that Jay Hagan, President and Chief Executive Officer of Regulus, will present at the 20th Annual Needham Healtchare Conference

Anthem, Inc. announced that it will provide a $50 incentive to all associates who are fully vaccinated against COVID-19.

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will host a virtual R&D Day on Wednesday, April 14, 2021 beginning at 12:30 p.m. ET.

Lantheus Holdings, Inc., an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, announced the hiring of Dr. Bela Denes and Dr. Iryna Teslenko.